Replies to post #14653 on Predictive Technology Group Inc (PRED)

[High_Profits]

Thank you Thomas - Very Valuable Indeed

[reverse_long]

::::::::Yawn::::::

Worthless news. Give us something to date that is applicable!

[snow]

Thomas I find the information you present very interesting if it isnot very difficult to help the women involved once the disease has been established.

[Dante Fantasia]

Hello Thomas,

I have seen no such results for the ARTguide published by the company or in peer-reviewed journals (which does not mean your claim is invalid)--but a 97% detection rate is huge--and since such is not in the public domain, could you please augment our own DD by elucidating on this a bit (at least what you are publically allowed to do).

Specifically, what are the confidence intervals around such a statistic, and/or models used to derive proof of such efficacy? Could you please clarify if the results were generalizable beyond non-caucasian women, as I remember there being a caveat about the company's database limitation in that area and hence affect market size estimates? Has any statistical analysis looked at the sensitivity/specificity (or more broadly Type I vs II error tradeoff of the diagnostic)?

Further, in the past, Taylor's work at Yale was on a predictive endometriosis test currently on the market by a colleague at Yale. Is this an extension of that work or different, and in what way in what improved? It struck me as a bit unusual for Taylor to have broken ranks within Yale to do this similar work for PRED (e.g., DotLab) also see: https://medicine.yale.edu/obgyn/kliman/Images/GnRH%20Antagonists%202007_tcm607-154149.pdf and interestingly, his senior authorship with respect to applications in endometrial cancer detection (which may/may not be related to what he brings to PRED or does separately): https://medicine.yale.edu/obgyn/kliman/Images/Flannery%20J%20Clin%20EndocrinolMetab101-%202883%E2%80%932891%2C%202016_tcm607-296347.pdf .

I fully agree that if this is a valid (and surely will be scrutinized at the ASRM), this will be a home-run in itself. The ability, if valid, to go beyond the diagnosis of non-caucasian women (even the Asian segment) would make it a grand slam. Any details you could share of the science and more on Taylor and his seemingly divergent interests between his work at PRED and Yale, which appear to be competing would be very interesting and relevant to shareholders.


Thanks!

Maz

[biigboy7]

This, I believe, is the key to a big piece that will make $PRED billions. It's been a tough ride but hopefully this rollercoaster is going to be going forward in a big way next week!